



Aurobindo Pharma receives nine product approvals from MCC – South Africa

Aurobindo Pharma Ltd is pleased to announce that it has received approvals from the Medicines Control Council (MCC) to manufacture and market 9 products in South Africa. These products are estimated to have a generic market size of ZAR 165 million in the local market

The products approved are as follows:

#	Product Name	Active Ingredient	Dosage Form	Strength	Category
1	Auro-Lisinopril Co	Lisinopril+HCTZ	FDC	10+12.5mg, 20+12.5mg	CVS
2	Auro-Amlodipine	Amlodipine	Tablet	5mg, 10mg	CVS
3	Auro-Finasteride	Finasteride	Tablet	5mg	BPH
4	Zinoxime	Cefuroxime Axetil	Tablet	125mg, 250mg, 500mg	Anti-infective
5	Zolid	Sertraline HCL	Tablet	50mg, 100mg	CNS
6	Yomax	Amoxycillin	Capsules	250mg, 500mg	Anti-infective
7	Lazivir	Lamivudine/Zidovudine+Abacavir	FDC	150/300+300 mg	ARV
8	Lisinozide	Lisinopril+HCTZ	Tablet	10mg, 20mg	CVS
9	Profina	Finasteride	Tablet	5mg	BPH

(FDC Fixed Dose Combination, CVS: Cardio Vascular System, BPH: Benign Prostatic Hyperplasia, CNS: Central Nervous System, ARV: Anti-RetroVirals)

Aurobindo now has a total of 31 marketing authorizations approved by the MCC

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for several facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar
Ameerpet, Hyderabad
Phone: 040-66725000
Email: ir@aurobindo.com